Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.

IF 4.5 2区医学 Q1 HEMATOLOGY

Bone Marrow Transplantation Pub Date : 2024-10-18 DOI:10.1038/s41409-024-02435-8

Olaf Penack, Christophe Peczynski, William Boreland, Jessica Lemaitre, H Christian Reinhardt, Ksenia Afanasyeva, Daniele Avenoso, Tobias A W Holderried, Brian Thomas Kornblit, Eleni Gavriilaki, Carmen Martinez, Patrizia Chiusolo, Maria Caterina Mico, Elisabeth Daguenet, Stina Wichert, Hakan Ozdogu, Agnieszka Piekarska, Francesca Kinsella, Grzegorz W Basak, Hélène Schoemans, Christian Koenecke, Ivan Moiseev, Zinaida Peric

引用次数: 0

查看原文本刊更多论文

更正：ECP与Ruxolitinib治疗类固醇难治性慢性GVHD--EBMT移植并发症工作组的一项回顾性研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone Marrow Transplantation 医学-免疫学

CiteScore

8.40

自引率

8.30%

发文量

337

审稿时长

6 months

期刊介绍： Bone Marrow Transplantation publishes high quality, peer reviewed original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation. The broad scope of the journal thus encompasses topics such as stem cell biology, e.g., kinetics and cytokine control, transplantation immunology e.g., HLA and matching techniques, translational research, and clinical results of specific transplant protocols. Bone Marrow Transplantation publishes 24 issues a year.